Research

Research topics

Experimental and clinical pharmacokinetics of cardiovascular, antidepressant, anti-inflammatory and antibacterial drugs.

Pharmacokinetics of chiral drugs.

Studies of metabolism and membrane transport mechanisms.

Evaluation of drug pharmacokinetics in inflammatory disease models.

New treatments for sepsis in experimental animal models.

Pharmacokinetic-pharmacodynamic modeling (PK/PD) as a tool in new drug research.

Use of population pharmacokinetics in pharmacotherapy optimization.

Studies of the structure-pharmacokinetic (QSPKR) relationships of new xanthine derivatives.

Biomaterials as potential drug carriers – in vitro and in vivo studies.

Applied methods

High performance liquid chromatography, equilibrium dialysis, ultrafiltration, real-time polymerase chain reaction, ELISA, flow cytometry, isolated perfused organs.

Scientific equipment

HPLC with DAD, electrochemical and spectrofluorimetric detection, LC-MS/MS, real-time DNA detection system (Rotor Gene 3000), capillary electrophoresis apparatus (PACE/MDQ), drug dissolution testing system (flow-through method), perfusion system for isolated organs of small animals (mice, rats), kit for Microdialysis (CMA Microdialysis).

Publications

2019

“KSK19 – Novel histamine H3 receptor ligand reduces body weight in diet induced obese mice.” Kotańska M, Mika K, Reguła K, Szczepańska K, Szafarz M, Bednarski M, Olejarz-Maciej A, Nowak K, Latacz G, Mogilski S, Kuder KJ, Kieć-Kononowicz K, Sapa J. Biochem Pharmacol. 2019 Oct;168:193-203. doi: 10.1016/j.bcp.2019.07.006. Epub 2019 Jul 8.

“Structural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H3 receptor ligands.” Szczepańska K, Karcz T, Siwek A, Kuder KJ, Latacz G, Bednarski M, Szafarz M, Hagenow S, Lubelska A, Olejarz-Maciej A, Sobolewski M, Mika K, Kotańska M, Stark H, Kieć-Kononowicz K.Bioorg Chem. 2019 Oct;91:103071. doi: 10.1016/j.bioorg.2019.103071. Epub 2019 Jun 20.

“Pharmacokinetic considerations for current state-of-the-art antidepressants.” Wyska E. Expert Opin Drug Metab Toxicol. 2019 Sep 23:1-17. doi: 10.1080/17425255.2019.1669560.

“Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.” Socała K, Wyska E, Szafarz M, Nieoczym D, Wlaź P. Neuropharmacology. 2019 Nov 1;158:107733. doi: 10.1016/j.neuropharm.2019.107733. Epub 2019 Aug 1

“Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.” Świerczek A, Jankowska A, Chłoń-Rzepa G, Pawłowski M, Wyska E. Curr Drug Targets. 2019 Aug 1. doi: 10.2174/1389450120666190801114210.

“Characterization of the Brain Penetrant Neuropeptide Y Y2 Receptor Antagonist SF-11.” Domin H, Piergies N, Pięta E, Wyska E, Pochwat B, Wlaź P, Śmiałowska M, Paluszkiewicz C, Szewczyk B.ACS Chem Neurosci. 2019 Aug 21;10(8):3454-3463. doi: 10.1021/acschemneuro.9b00082. Epub 2019 Jul 3.

“Agomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A2A receptor antagonist, but not DPCPX, a selective adenosine A1 receptor antagonist.” Szopa A, Bogatko K, Serefko A, Wyska E, Wośko S, Świąder K, Doboszewska U, Wlaź A, Wróbel A, Wlaź P, Dudka J, Poleszak E. Pharmacol Rep. 2019 Aug;71(4):676-681. doi: 10.1016/j.pharep.2019.03.007. Epub 2019 Mar 16.

“Influence of the CB1 cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in mice.” Poleszak E, Wośko S, Sławińska K, Wyska E, Szopa A, Doboszewska U, Wlaź P, Wlaź A, Dudka J, Szponar J, Serefko A.Brain Res Bull. 2019 Aug;150:179-185. doi: 10.1016/j.brainresbull.2019.05.021. Epub 2019 May 31.

“Beneficial effects of non-quinazoline α1-adrenolytics on hypertension and altered metabolism in fructose-fed rats. A comparison with prazosin.” Kubacka M, Kotańska M, Szafarz M, Pociecha K, Waszkielewicz AM, Marona H, Filipek B, Mogilski S.Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):751-760. doi: 10.1016/j.numecd.2019.04.003. Epub 2019 Apr 13.

“Effect of Pterostilbene, a Natural Analog of Resveratrol, on the Activity of some Antiepileptic Drugs in the Acute Seizure Tests in Mice.” Nieoczym D, Socała K, Jedziniak P, Wyska E, Wlaź P. Neurotox Res. 2019 Mar 15. doi: 10.1007/s12640-019-00021-1. [Epub ahead of print]

“Novel aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) phosphorylation-preferring serotonin 5 HT1A receptor biased agonists with robust antidepressant-like activity.” Sniecikowska J, Głuch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzębska-Więsek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski MH, Varney M, Newman-Tancredi A, Kołaczkowski M. J Med Chem. 2019 Feb 5. doi: 10.1021/acs.jmedchem.9b00062.

“Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist.” Poleszak E, Szopa A, Bogatko K, Wyska E, Wośko S, Świąder K, Doboszewska U, Wlaź A, Wróbel A, Wlaź P, Serefko A.Neurotox Res. 2019 Feb;35(2):344-352. doi: 10.1007/s12640-018-9959-2.

“Anticonvulsant Activity of Pterostilbene in Zebrafish and Mouse Acute Seizure Tests.” Nieoczym D, Socała K, Gawel K, Esguerra CV, Wyska E, Wlaź P. Neurochem Res. 2019 Jan 28. doi: 10.1007/s11064-019-02735-2.

 

2018

“DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests.” Szopa A, Poleszak E, Bogatko K, Wyska E, Wośko S, Doboszewska U, Świąder K, Wlaź A, Dudka J, Wróbel A, Wlaź P, Serefko A. Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1361-1371. doi: 10.1007/s00210-018-1551-z. Epub 2018 Aug 9.

“Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans.” Świerczek A, Wyska E, Pociecha K, Baś S, Mlynarski J.Xenobiotica. 2018 Dec 11:1-12. doi: 10.1080/00498254.2018.1542516.

“Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.” Chłoń-Rzepa G, Ślusarczyk M, Jankowska A, Gawalska A, Bucki A, Kołaczkowski M, Świerczek A, Pociecha K, Wyska E, Zygmunt M, Kazek G, Sałat K, Pawłowski M.Eur J Med Chem. 2018 Sep 10;158:517-533. doi:10.1016/j.ejmech.2018.09.021.

“Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.” Jankowska A, Swierczek A, Wyska E, Gawalska A, Bucki A, Pawlowski M, Chlon-Rzepa G. Curr Drug Targets. 2018 Aug 7. doi: 10.2174/138945011966618080810505

“The influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in mice.” Bogatko K, Poleszak E, Szopa A, Wyska E, Wlaź P, Świąder K, Wlaź A, Doboszewska U, Rojek K, Serefko A.
J Pharm Pharmacol. 2018 Sep;70(9):1200-1208. doi: 10.1111/jphp.12954. Epub 2018 Jun 25.

“Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes.” Szopa A, Poleszak E, Doboszewska U, Herbet M, Świąder K, Wyska E, Serefko A, Wlaź A, Korga A, Ostrowska M, Juś P, Jedynak S, Dudka J, Wlaź P. Psychopharmacology (Berl). 2018 Jun 7. doi: 10.1007/s00213-018-4940-6

“The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices.” Krupa A, Tabor Z, Tarasiuk J, Strach B, Pociecha K, Wyska E, Wroński S, Łyszczarz E, Jachowicz R. Eur J Pharm Sci. 2018 Jul 1;119:234-243. doi: 10.1016/j.ejps.2018.04.023. Epub 2018 Apr 19.

“Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.” Socała K, Nieoczym D, Pieróg M, Wyska E, Szafarz M, Doboszewska U, Wlaź P. Neurotox Res. 2018 Feb 9. doi: 10.1007/s12640-018-9876-4.

“Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.” Chłoń-Rzepa G, Jankowska A, Ślusarczyk M, Świerczek A, Pociecha K, Wyska E, Bucki A, Gawalska A, Kołaczkowski M, Pawłowski M.Eur J Med Chem. 2018 Feb 25;146:381-394. doi: 10.1016/j.ejmech.2018.01.068. Epub 2018 Feb 4.

 

2017

Socała K, Nieoczym D, Kowalczuk-Vasilev E, Wyska E, Wlaź P. “Increased seizure susceptibility and other toxicity symptoms following acute sulforaphane treatment in mice”.Toxicol Appl Pharmacol. 2017 Jul 1;326:43-53. doi: 10.1016/j.taap.2017.04.010. Epub 2017 Apr 13.

Przejczowska-Pomierny K, Włodyka M, Cios A, Wyska E.“Enantioselective analysis of ibuprofen enantiomers in mice plasma and tissues by high-performance liquid chromatography with fluorescence detection: Application to a pharmacokinetic study”. Chirality. 2017 Sep;29(9):500-511. doi: 10.1002/chir.22715. Epub 2017 Jul 5.

Krupa A, Cantin O, Strach B, Wyska E, Tabor Z, Siepmann J, Wróbel A, Jachowicz R., “In vitro and in vivo behavior of ground tadalafil hot-melt extrudates: How the carrier material can effectively assure rapid or controlled drug release”. Int J Pharm. 2017 Aug 7;528(1-2):498-510. doi: 10.1016/j.ijpharm.2017.05.057. Epub 2017 May 27.

Szafarz M, Kus K, Walczak M, Zakrzewska A, Niemczak M., Pernak J., Chlopicki S. Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. J Pharm Sci. 2017 May; 106(5):1412-1418. DOI 10.1016/j.xphs.2017.01.022. Epub 2017 Jan 30.

Jankowska A, Świerczek A, Chłoń-Rzepa G, Pawłowski M, Wyska E. PDE7- Selective and Dual Inhibitors: Advances in Chemical and Biological Research. Curr Med Chem. 2017 Jan 16.

Stasiuk W, SzopaA, Serefko A, Wyska E, Świąder K, Dudka J, Wlaź P, Poleszak E. Influance of the selective antagonist of the NR2B subunit of the NMDA receptor, traxopodil, of the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. J Neural Transm (Vienna). 2017 Mar;124(3):387-396. Doi: 10.1007/s00702-016-1657-8. Epub. 2016 Nov 29.

Socała K, Nieoczym D, Wyska E, Wlaź P. Effect  of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.  Naunym Schmiedebergs Arch Pharmacol. 2017 Apr;390(4);339-349. DOI: 10.1007/s00210-016-1334-3. Epub 2016 Dec 24. 

Sałat K, Podkowa A, Malikowska N, Kern F, Pabel J, Wojciaszak E, Kulig K, Wanner K, Strach B, Wyska E. Novel, highly potent and in vitro active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and natinociceptive properties. Neuropharmacology 113 (2017) 331-342 DOI: 10-1016/ j.neuropharm.2016.10.019

 

2016

Attard D, Shoemake C, Vella J, Żmudzki P, Chłoń-Rzepa G, Wyska E. Evaluation and Optimization of In Silico Designed PDE4B Modulators. Am J Pharmtech Res. 2016, 6(5), 623-639.

Stasiuk W, Serafko A, Szopa A, Wyska E, Świąder K, Wlaź P, Polaszek E. Traxoprodil augments the antidepressant-likeactivvity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice. Pharmacol. Rep, 2016 Vol.68, nr 5 960-963

Wyska E, Świerczek A, Pociecha K, Przejczowska-Pomierny K. Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Eur. J. Drug Metab. Pharmacokinet. 2016: Vol. 41, s. 403-412

Zakrzewska A, Szafarz M, Kuś K, Kij A, Gonciarz A, Walczak M. Quantyfication and pharmacokinetics of 1-methylpyridinium and 1,4-dimethylpyridinium in rats by liquid chromatography tandem mass spectrometry. Tissue distribution of 1,4-dimethylpyridium in rats. Acta Poloniae Pharmaceutica – Drugs Resarch Vol. 73 No. 5 pp 1111-1121 

Krupa A., Descamps M, Willart JF, Strach B, Wyska E., Jachowicz R, Danède F. High-energy ball milling as green process to vitrify tadalafil and improve bioavailaility. Molecular Pharmaceutics DOI: 10.1021/acs.molpharmaceut.6b00688 2016 September 12

Zygmunt M., Chłoń-Rzepa G, Wyska E, Pociecha K, Sapa J. Anti-inflammatory and antioxidant activity of 8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl derivatives with terminal carboxylic, ester or amide moieties in animal models. Acta Poloniae Phamaceutica – Drug Research 2016; 73 761-770.

Socała K, Nieoczym D, Pieróg M, Szuster – Ciesielska A, Wyska E, Wlaź P. Antidepressant – like activity of sildenafil following acure and subchronic treatment in the forced swim test in mice: effects of restraint stress and monoamine depletion. Metab Brain Dis. 2016 Jun 10

Poleszak E, Stasiuk W, Szopa A, Wyska E, Serefko A, Oniuszczuk A, Wośko S, Świąder K, Wlaź P. Traxoprodil, a selective antagonist of the NR2B subunit of the MNMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Met Brain Dis. 2016 Feb 20

Poleszak E, Szopa A, Wyska E, Serafko A., Kukuła – Koch W, Wośko S, Bogatko K, Wróbel A, Wlaź P. Caffeine augments the antidepressants-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice. Pharmacol Rep. 2016 Feb 68(1):56-61 DOI: 10.1016/j.pharep.2015.06.138

Szopa A, Poleszak E, Wyska E, Serefko A, Wośko S, Wlaź S, Pieróg M, Wróbel A, Wlaź P, Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. Naunym Schmiedebergs Arch Pharmacol. 2016 389:211-21

 

Scientific Collaboration

  • Institute of Nuclear Physics, Polish Academy of Sciences
  • Department of Animal Physiology, Faculty of Biology and Biotechnology UMCS
  • Department of Pharmacokinetic and Therapeutic Therapy, Faculty of Medicine, PUM

Department of Ceramics and Refractory Technology, Faculty of Materials Science and Ceramics,

Wielkość fontu
Kontrast